Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -105.20% is 267% below its 5-year average of -28.66%, near the low end of its 5-year range (-105.20%–-12.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 33.38% below its 12-month average of -78.88%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -105.20%.
RETURN ON EQUITY (ROE)
-105.20%
RETURN ON EQUITY (ROE) AVG TTM
-78.88%
RETURN ON EQUITY (ROE) AVG 3Y
-49.25%
RETURN ON EQUITY (ROE) AVG 5Y
-28.66%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-33.38%
CURRENT VS 3Y AVG
-113.60%
CURRENT VS 5Y AVG
-267.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-150.42%
vs the sector median at left
PMV Pharmaceuticals, Inc.
Market Cap
$89.86M
Return on Equity (ROE)
-105.20%
TTM Avg
-78.88%
3Y Avg
-49.25%
5Y Avg
-28.66%
Market Cap
$89.45M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$89.53M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$89.84M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$89.12M
Return on Equity (ROE)
-477.87%
TTM Avg
-156.51%
3Y Avg
-83.51%
5Y Avg
-25.98%
Market Cap
$89.69M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
Market Cap
$91.05M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$91.46M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$83.61M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $89.86M | -105.20% | -78.88% | -49.25% | -28.66% |
| CareCloud, Inc. (CCLD)vs › | $89.45M | 45.93% | 16.96% | -19.36% | -13.87% |
| electroCore, Inc. (ECOR)vs › | $89.53M | N/A | 329.82% | 69.21% | 21.28% |
| ImmuCell Corporation (ICCC)vs › | $89.84M | 2.51% | -5.84% | -10.75% | -7.81% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $89.12M | -477.87% | -156.51% | -83.51% | -25.98% |
| Rallybio Corporation (RLYB)vs › | $89.69M | 48.20% | -54.60% | -54.70% | -44.17% |
| Equillium, Inc. (EQ)vs › | $91.05M | -32.15% | -60.32% | -93.79% | -79.41% |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | -268.09% | -238.76% | -155.55% | -124.74% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.61M | N/A | 1.45% | 25.22% | -14.52% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $91.18M | -11.85% | -51.56% | -105.39% | -105.39% |
ROE
-105.2%
ROA
-91.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -105.20% |
| 2026-03-31 | -89.06% |
| 2025-12-31 | -74.24% |
| 2025-09-30 | -68.35% |
| 2025-06-30 | -57.52% |
| 2025-03-31 | -38.02% |
| 2024-12-31 | -33.34% |
| 2024-09-30 | -26.00% |
| 2024-06-30 | -22.81% |
| 2024-03-31 | -30.61% |
| 2023-12-31 | -30.56% |
| 2023-09-30 | -30.53% |
| 2023-06-30 | -34.04% |
| 2023-03-31 | -32.15% |
| 2022-12-31 | -29.80% |
| 2022-09-30 | -27.69% |
| 2022-06-30 | -24.95% |
| 2022-03-31 | -22.16% |
| 2021-12-31 | -18.75% |
| 2021-09-30 | -15.37% |
| 2021-06-30 | -12.93% |
| 2021-03-31 | -11.14% |
| 2020-12-31 | -9.59% |
| 2020-09-30 | -8.41% |
| 2020-06-30 | -33.89% |
